We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Biomarker Predicts Dementia in Cerebral Small Vessel Disease

By LabMedica International staff writers
Posted on 24 Feb 2021
Print article
Image: The Simoa HD-1 Analyzer is a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing (Photo courtesy of Quanterix).
Image: The Simoa HD-1 Analyzer is a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing (Photo courtesy of Quanterix).
Cerebral small vessel disease (SVD) is a highly prevalent condition, which causes lacunar stroke, vascular cognitive impairment and vascular dementia. Few treatments have been shown to delay disease progression.

Neurofilament light chain (NfL) is a blood marker sensitive to neuroaxonal damage and increased levels occur in neurodegenerative diseases. In a cross-sectional study in SVD, NfL levels were associated with cognition and disability. However, if NfL is to be used to predict outcome, studies are required to demonstrate baseline NfL predicts future dementia risk.

An international team of scientists associated with the University of Cambridge (Cambridge, UK) enrolled a total of 121 patients with symptomatic SVD, defined as a clinical lacunar stroke syndrome with MRI evidence of an anatomically corresponding lacunar infarct, at least three months post stroke. Of the 121 subjects recruited, blood was available for 113, and in 90 patients blood samples were available from at least at two time points. Average baseline age was 70, and 74% of participants were men.

Serum Nfl analysis was the same for all samples using the same single-molecule array instrument, the Simoa HD-1 (Quanterix, Billerica, MA, USA). The team used the capture monoclonal antibody (mAB) 47:3 and the biotinylated detector mAB 2:1 (UmanDiagnostics, Umeå, Sweden), transferred onto the Simoa platform.

The team reported baseline serum NfL levels averaged 36.51 pg/mL. Cross-sectional analyses showed NfL levels were inversely associated with global cognitive function, executive function, and processing speed. They also were negatively correlated with disability. Higher NfL levels were positively associated with lacune count, cerebral microbleed count, white matter hyperintensities, and diffusion tensor imaging (DTI) measures, and were negatively associated with normalized brain volume.

Over five years, both global cognition and processing speed declined significantly. Higher NfL at baseline predicted lower function in global cognition independently of clinical markers and baseline cognition. A total of 107 participants had complete baseline DTI and NfL data; 19 of them converted to dementia over time. Higher baseline NfL predicted not only dementia, but changes in lacune count, microbleed count, and brain volume, independently of initial MRI baseline values and patient age.

The authors concluded that prospective cohort study demonstrates that baseline NfL values predict cognitive decline and dementia rate over a five years follow-up duration in patients with severe SVD. NfL may be a useful prognostic marker in this disease. However, in contrast to diffusion tensor imaging (DTI), change in NfL values was not detected over a three years follow-up period with annual sampling, suggesting NfL is unlikely to be a useful surrogate marker in a phase 2 clinical trial. The study was published on February 8, 2021 in the Journal of Neurology, Neurosurgery, and Psychiatry.

Related Links:
University of Cambridge
Quanterix
UmanDiagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.